INHIBITION OF THE FACTOR XA (WITH RIVAROXABAN) SLOW DOWN PROGRESSION, PREVENTS COMPLICATION AND DECREASE MORTALITY IN CORONARY HEART DISEASE
A review presented, of the novel scientific data, mostly the results of large clinical trials, witnessing on clinical efficacy and safety of rivaroxaban — the anticoagulant, selective blocker of Xa factor — in treatment of acute and chronic coronary heart disease. The mechanisms explained, of the dr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2018-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2753 |